Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

ABSTRACT: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

PROVIDER: PRJNA736761 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

Project description:Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

| PRJNA736762 | ENA

Genomic copy number number characterisation of glioblastoma (GBM) cell lines.

Project description:Genomic copy number number characterisation of glioblastoma (GBM) cell lines.

| PRJNA489666 | ENA

Single-cell copy number analysis in melanoma

Project description:Single-cell copy number analysis in melanoma

| PRJNA635693 | ENA

Great Ape Copy Number Variation

Project description:Great Ape Copy Number Variation

| PRJNA144461 | ENA

Ty Copy Number Control

Project description:Evolution of transposable element copy number control in yeast

| PRJEB33725 | ENA

Copy Number Variations in Genomic Disorders

Project description:Copy Number Variations in Genomic Disorders

| PRJNA75521 | ENA

Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.

Project description:Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.

| S-EPMC8361159 | biostudies-literature

Copy number variation analysis of nasopharyngeal carcinoma cell lines

Project description:To analyze the global copy number aberrations of two nasopharyngeal carcinoma cell lines, TW01 and HONE1. Global copy number aberrations were analyzed by using high-resolution oligoarray CGH on two NPC cell lines, TW01 and HONE1. The overviews of array CGH profiles reveal high similarity between both NPC cell lines, but the degree of copy-number alterations were more severe in TW01 than in HONE1. There were 1204 and 1513 genes with copy-number gain (CNVs with aberration score > 0.5 and number of contiguous probes ≥ 3) in TW01 and HONE1, respectively. Among them, 850 were commonly amplified in both cell lines (Gain-TH). There were 3525 genes and 926 genes with copy-number loss (CNVs with aberration score < 0.5 and number of contiguous probe ≥ 3) in TW01 and HONE1, respectively. Among them, 582 were commonly deleted in both cell lines (Loss-TH). The most prominent CNVs observed including gain on 3q26.2-q26.31, loss on 3p21.2-q12.1, 9p24.3-p21.3, and nearly the whole Y chromosome.

2010-03-09 | GSE15172 | GEO

Copy number of oral cell lines [CGH]

Project description:Profiling of copy number mutations in commonly used non-cancerous oral cell lines

2014-07-15 | GSE59406 | GEO

Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma

Project description:Anal squamous cell carcinoma (ASCC) is an infrequent tumor. Since 70s, treatment of stages II-III consists on a combination of 5-fluorouracil (5FU), mitomycin C (MMC), and radiotherapy. The aim of this study is the identification of biomarkers that allow personalized treatment and improvement of therapeutic outcomes. Forty-six tumor paraffin samples from ASCC patients were analyzed by whole-exome sequencing. Single nucleotide polymorphisms and copy number variants (CNVs) were identified and their relation to disease-free survival (DFS) was studied using BRB Array Tool and Kaplan-Meier analyses. Obtained findings were validated in an independent retrospective cohort of 101 ASCC patients with stages I-III from eleven hospitals within the Multidisciplinary Spanish Digestive Cancer Group (GEMCAD) using qPCR Copy Number Assays. GEMCAD validation cohort was also analyzed using mass spectrometry proteomics to assess the biological features of these tumors.

2023-04-26 | PXD037816 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data